Spruce Biosciences, Inc. (SPRB)

In September 2025, Spruce Biosciences resumed trading on the Nasdaq Capital Market following a reverse stock split. In October 2025, the company secured approximately $50 million through a private placement, extending its cash runway into Q4 2026. In January 2026, Spruce Biosciences entered a loan facility with Avenue Capital for up to $50 million. In February 2026, positive Type B meetings with the FDA for TA-ERT de-risked the path to accelerated approval. The BLA submission for TA-ERT shifted from Q1 to Q4 2026, leading to some analysts reducing their price targets. Spruce Biosciences reported its full-year 2025 financial results on March 9, 2026. As of March 27, 2026, the stock price was $63.04 per share, representing a significant increase from March 31, 2025.

There is no indication of demand seasonality for Spruce Biosciences' products and services, as demand is driven by medical need and regulatory approvals rather than seasonal fluctuations.

Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for rare endocrine and neurological disorders. The company uses a precision medicine approach to advance treatment candidates through late-stage clinical trials. Its lead therapy, tralesinidase alfa (TA-ERT), is an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB) and has received FDA Breakthrough Therapy Designation. The company is also developing tildacerfont for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), as well as SPR202 for CAH.

Spruce Biosciences is headquartered in South San Francisco, California. The company has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.

Specific information detailing Spruce Biosciences, Inc.'s brand reputation is not extensively covered in the provided search results. The positive FDA Breakthrough Therapy Designation for TA-ERT and positive Type B meetings with the FDA would generally contribute positively to the company's scientific and regulatory standing.

As of March 27, 2026, Spruce Biosciences has 36 institutional owners and shareholders holding a total of 728,584 shares, with institutional investors owning 91.71% of the stock. Major institutional shareholders include Ikarian Capital, LLC, Squadron Capital Management LLC, Citadel Advisors Llc, Wellington Management Group Llp, ADAR1 Capital Management, LLC, Alyeska Investment Group, L.P., Boothbay Fund Management, Llc, Balyasny Asset Management Llc, Carlyle Group Inc., and Schonfeld Strategic Advisors LLC. Insiders hold 6.90% of the stock.